Will a new, more powerful syringe be Novo Nordisk’s revenge in the obesity war? Or a completely new hormone? After austerity packages, a change of CEO and a new board, the company’s leading researchers will try to reverse the trend.
New Class of Anti-Obesity Drugs in Development
